Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — Q1 FY2023 Earnings Presentation
11 slides from Angiodynamics's earnings presentation, Oct 6, 2022
Slide 1: First Quarter 2023 Earnings Presentation
ANGIODYNAMICS First Quarter 2023 Earnings Presentation October 6, 2022 1
Slide 2: Forward-Looking Statement
2 Forward-Looking Statement Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations,
Slide 3: Corporate Developments – Q1 FY23 Highlights
Corporate Developments – Q1 FY23 Highlights Continued focused investment in our 3 key Med Tech platforms: Auryon, Thrombus Management & NanoKnife Macroeconomic headwinds persist Gross margin impacted by supply chain disruptions, labor shortages, freight and inflation Backlog reduced by $1.3 million
Slide 4: Q1 FY23 Highlights
Q1 FY23 Highlights Q1 FY23 Q1 FY22 Change Revenue $81,537 $76,971 5.9% Gross Margin Med Tech Med Device 51.9% 63.2% 47.5% 52.1% 65.4% 48.2% (20 bps) (220 bps) (70 bps) Net Loss ($13,004) ($6,972) ($6,032) GAAP EPS ($0.33) ($0.18) ($0.15) Adjusted EPS ($0.06) ($0.02) ($0.04) Adjusted EBITDA $2,961 $3
Slide 5: Sales Comparison to Prior-Year Periods
Sales Comparison to Prior-Year Periods 5 Med Tech Q1 FY23 Auryon 50.0% Thrombus Management* AngioVac AlphaVac** 31.8% 8.5% N/A NanoKnife® Disposables 12.3% NanoKnife® Capital (37.2%) Med Device Q1 FY23 Solero® Microwave 6.1% BioSentry (13.4%) Core Peripheral 5.3% Venous (7.8%) Alatus and IsoLoc Ball
Slide 6: Q1 FY23 Results (unaudited)
Q1 FY23 Results (unaudited) $ in thousands (except per share data) Q1 FY23 Q1 FY22 Change Revenue $81,537 $76,971 5.9% Med Tech Med Device $22,817 $58,720 $17,607 $59,364 29.6% (1.1%) United States International $69,023 $12,514 $64,464 $12,507 7.1% 0.1% Net Loss Non-GAAP Adjusted Net Income (Loss) (
Slide 7: Q1 FY23 Gross Margin Walk
Q1 FY23 Gross Margin Walk 80 Bps (100 Bps) = | (60 Bps) (80Bps) 240BPs Tight ql Price / Material Labor Freight Laser Production& QI FY22 Mix Inflation Market Inflation Placements Operations FY23 i>) angiodynamics
Slide 8: Q1 FY23 Cash Walk
8 Q1 FY23 Cash Walk (in millions)
Slide 9: FY23 Guidance Reaffirmed
FY23 Guidance 9 FY23 Guidance Reaffirmed Q4 FY2022 Revenue $342 - $348 million Gross Margin Med Tech Med Device 52.5% - 54.5% 65% - 68% 45% - 48% Adjusted EPS $0.01 - $0.06
Slide 10: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation 10
Slide 11: Reconciliation of GAAP to Non-GAAP Net Loss and EPS
Reconciliation of GAAP to Non-GAAP Net Loss and EPS Reconciliation of Net Loss to Adjusted EBITDA Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items. Adjustment to reflect the